#IAS25: Q&A with International AIDS Society leader on HIV funding, eradicating AIDS and more KIGALI, RWANDA — Four decades into the HIV epidemic, the significance of conferences can easily be forgotten. But the International AIDS Society’s meeting on HIV Science this week in Rwanda will likely be remembered as ...

Thoughts on this? >> #IAS25: Q&A with International AIDS Society leader
on HIV funding, eradicating AIDS and more >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #pharma #productmarketing

#IAS25: Jeanne Marrazzo, NIAID director placed on leave, on 'biggest threats' to HIV medicine KIGALI, RWANDA — A federal health official put on leave by the Trump administration is calling for sustained investment in HIV research. The remarks are some of the first that Jeanne Marrazzo has delivered since she ...

Thoughts on this? >> #IAS25: Jeanne Marrazzo, NIAID director placed on leave, on
'biggest threats' to HIV medicine >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #pharma #productmarketing

#IAS25: As PEPFAR funding gets congressional support, HIV leaders warn of regression for the field KIGALI, RWANDA — The opening night message was clear. “UNAIDS warns that if urgent steps are not taken, we may find ourselves back in the dismal era of 2000. We must all agree here today ...

Thoughts on this? >> #IAS25: As PEPFAR funding gets congressional support, HIV
leaders warn of regression for the field >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare

Today is poster session at #IAS25 in Kigali, Rwanda 👶📊

⬇️Check out the #EMPIRICAL results on infants living with #HIV and severe #pneumonia:

⚠️ Analysis of causes of death
🧪 Empirical treatment of #CMV and #tuberculosis

#EDCTP3 #GlobalHealth #Pediatrics @iasociety.bsky.social

#IAS25: WHO adds Gilead's twice-yearly injection to global PrEP guidelines KIGALI, RWANDA — Weeks after the FDA's watershed approval of Gilead's twice-yearly HIV prevention injection, the World Health Organization recommended the product to further stop the spread of HIV. The WHO on ...

Thoughts on this? >> #IAS25: WHO adds Gilead's twice-yearly injection to global
PrEP guidelines >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #pharma #healthcare

#IAS25: Merck sends new monthly oral PrEP to Phase 3 after earlier islatravir setback KIGALI, RWANDA — Three years after a safety disappointment halted earlier plans for a once-monthly HIV PrEP candidate, Merck is back in the late stages of development with a next-generation effort. The New Jersey company said ...

Thoughts on this? >> #IAS25: Merck sends new monthly oral PrEP to Phase 3 after
earlier islatravir setback >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech

#IAS25: GSK's ViiV expands licensing pact to include long-acting HIV treatment KIGALI, RWANDA — ViiV Healthcare, the HIV-focused biotech that's majority-owned by GSK, said it's expanding its voluntary licensing agreement with the Medicines Patent Pool and three generic manufacturers to include its long-acting HIV treatment. ...

Thoughts on this? >> #IAS25: GSK's ViiV expands licensing pact to include
long-acting HIV treatment >> Comment below! #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing

Thank you Alfredo Tagarro and Kavidha Reddy for presenting on #EARTHcohort at #IAS25 #pediatrics. Great @pentafoundation.bsky.social results!

At #IAS25 important presentation by Alfredo Tagarro on #EARTH cohort viral reservoir results in #children living with #HIV, led by @pentafoundation.bsky.social and #EPIICAL 📊

@iasociety.bsky.social #CLHIV #pediatrics

As researchers come together for HIV conference, few biotechs can stay the course Key HIV researchers and experts to meet in Kigali for IAS conference as field faces biotech scarcity, with Gilead, ViiV Healthcare and Merck leading development efforts.

Researches are gathering in Rwanda for #IAS25 to discuss the latest advancements in HIV science. Biotechs, however, are struggling to carry forward R&D — especially new ones.
endpoints.news/ias25-as-res...